Cargando…
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026439/ https://www.ncbi.nlm.nih.gov/pubmed/36941575 http://dx.doi.org/10.1186/s12885-023-10699-4 |
_version_ | 1784909540703076352 |
---|---|
author | Slater, Susanna Bryant, Annette Chen, Hsiang-Chi Begum, Ruwaida Rana, Isma Aresu, Maria Peckitt, Clare Zhitkov, Oleg Lazaro-Alcausi, Retchel Borja, Victoria Powell, Rachel Lowery, David Hubank, Michael Rich, Thereasa Anandappa, Gayathri Chau, Ian Starling, Naureen Cunningham, David |
author_facet | Slater, Susanna Bryant, Annette Chen, Hsiang-Chi Begum, Ruwaida Rana, Isma Aresu, Maria Peckitt, Clare Zhitkov, Oleg Lazaro-Alcausi, Retchel Borja, Victoria Powell, Rachel Lowery, David Hubank, Michael Rich, Thereasa Anandappa, Gayathri Chau, Ian Starling, Naureen Cunningham, David |
author_sort | Slater, Susanna |
collection | PubMed |
description | BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy (ACT) decisions is non-inferior to standard of care (SOC) chemotherapy, as measured by 3-year disease free survival (DFS) in patients with resected CRC with no evidence of MRD (ctDNA negative post-operatively). In doing so we may be able to spare patients unnecessary chemotherapy and associated toxicity and achieve significant cost savings for the National Health Service (NHS). METHODS: We are recruiting patients with fully resected high risk stage II and stage III CRC who are being considered for ACT into the study which uses results from a plasma-only ctDNA assay to guide treatment decisions. Eligible patients are randomised 1:1 to receive ctDNA-guided chemotherapy versus SOC chemotherapy. The primary endpoint is the difference in DFS at 3 years between the trial arms. Secondary endpoints include the proportion of patients in the ctDNA-guided arm who are ctDNA negative post-operatively and receive de-escalated ACT compared to the standard arm, the difference in overall survival (OS), neurotoxicity and quality of life between the arms, and the cost-effectiveness of ctDNA-guided therapy compared to SOC treatment. We hypothesise that using a ctDNA-guided approach to ACT decisions is non-inferior to SOC. Target accrual is 1621 patients over 4 years, which will provide a power of 80% with an alpha of 0.1 to demonstrate non-inferiority with a margin of 1.25 in survival of the ctDNA-guided approach compared to SOC. We anticipate approximately 50 UK centres will participate. The study opened with the Guardant Reveal plasma-only ctDNA assay in August 2022. DISCUSSION: The trial will determine whether ctDNA guided ACT is non-inferior to SOC ACT in patients with fully resected high risk stage II and stage III resected CRC, with the potential to significantly reduce unnecessary ACT and the toxicity associated with it. TRIAL REGISTRATION: NCT04050345. |
format | Online Article Text |
id | pubmed-10026439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100264392023-03-21 ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) Slater, Susanna Bryant, Annette Chen, Hsiang-Chi Begum, Ruwaida Rana, Isma Aresu, Maria Peckitt, Clare Zhitkov, Oleg Lazaro-Alcausi, Retchel Borja, Victoria Powell, Rachel Lowery, David Hubank, Michael Rich, Thereasa Anandappa, Gayathri Chau, Ian Starling, Naureen Cunningham, David BMC Cancer Study Protocol BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy (ACT) decisions is non-inferior to standard of care (SOC) chemotherapy, as measured by 3-year disease free survival (DFS) in patients with resected CRC with no evidence of MRD (ctDNA negative post-operatively). In doing so we may be able to spare patients unnecessary chemotherapy and associated toxicity and achieve significant cost savings for the National Health Service (NHS). METHODS: We are recruiting patients with fully resected high risk stage II and stage III CRC who are being considered for ACT into the study which uses results from a plasma-only ctDNA assay to guide treatment decisions. Eligible patients are randomised 1:1 to receive ctDNA-guided chemotherapy versus SOC chemotherapy. The primary endpoint is the difference in DFS at 3 years between the trial arms. Secondary endpoints include the proportion of patients in the ctDNA-guided arm who are ctDNA negative post-operatively and receive de-escalated ACT compared to the standard arm, the difference in overall survival (OS), neurotoxicity and quality of life between the arms, and the cost-effectiveness of ctDNA-guided therapy compared to SOC treatment. We hypothesise that using a ctDNA-guided approach to ACT decisions is non-inferior to SOC. Target accrual is 1621 patients over 4 years, which will provide a power of 80% with an alpha of 0.1 to demonstrate non-inferiority with a margin of 1.25 in survival of the ctDNA-guided approach compared to SOC. We anticipate approximately 50 UK centres will participate. The study opened with the Guardant Reveal plasma-only ctDNA assay in August 2022. DISCUSSION: The trial will determine whether ctDNA guided ACT is non-inferior to SOC ACT in patients with fully resected high risk stage II and stage III resected CRC, with the potential to significantly reduce unnecessary ACT and the toxicity associated with it. TRIAL REGISTRATION: NCT04050345. BioMed Central 2023-03-20 /pmc/articles/PMC10026439/ /pubmed/36941575 http://dx.doi.org/10.1186/s12885-023-10699-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Slater, Susanna Bryant, Annette Chen, Hsiang-Chi Begum, Ruwaida Rana, Isma Aresu, Maria Peckitt, Clare Zhitkov, Oleg Lazaro-Alcausi, Retchel Borja, Victoria Powell, Rachel Lowery, David Hubank, Michael Rich, Thereasa Anandappa, Gayathri Chau, Ian Starling, Naureen Cunningham, David ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title | ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title_full | ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title_fullStr | ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title_full_unstemmed | ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title_short | ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) |
title_sort | ctdna guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage ii or stage iii colorectal cancer: a multi-centre, prospective, randomised control trial (tracc part c) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026439/ https://www.ncbi.nlm.nih.gov/pubmed/36941575 http://dx.doi.org/10.1186/s12885-023-10699-4 |
work_keys_str_mv | AT slatersusanna ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT bryantannette ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT chenhsiangchi ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT begumruwaida ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT ranaisma ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT aresumaria ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT peckittclare ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT zhitkovoleg ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT lazaroalcausiretchel ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT borjavictoria ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT powellrachel ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT lowerydavid ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT hubankmichael ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT richthereasa ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT anandappagayathri ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT chauian ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT starlingnaureen ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc AT cunninghamdavid ctdnaguidedadjuvantchemotherapyversusstandardofcareadjuvantchemotherapyaftercurativesurgeryinpatientswithhighriskstageiiorstageiiicolorectalcanceramulticentreprospectiverandomisedcontroltrialtraccpartc |